Marino Garcia
CEO and President at Dianthus Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Dianthus Therapeutics Inc., 3 years.
Dianthus Therapeutics Inc.
Director · CEO AND PRESIDENT
Chief executive roles
Dianthus Therapeutics Inc.
· CEO and President
Since September 2023
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Option exercise | +40,000 | $8.44 | $337,600 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Option exercise | +126,000 | $8.44 | $1,063,440 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −10,384 | $107.49 | $1,116,176 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −23,907 | $108.05 | $2,583,151 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −2,373 | $109.10 | $258,894 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −2,536 | $110.02 | $279,011 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −800 | $110.76 | $88,608 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −104,091 | $107.96 | $11,237,664 |
| Aug 7, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −21,909 | $108.72 | $2,381,946 |
| Mar 16, 2026 | Dianthus Therapeutics Inc. | Option exercise | +59,700 | $6.70 | $399,990 |
| Mar 16, 2026 | Dianthus Therapeutics Inc. | Option exercise | +5,592 | $17.88 | $99,985 |
| Mar 12, 2026 | Dianthus Therapeutics Inc. | Option exercise | +122,918 | $6.70 | $823,551 |
| Mar 12, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −43,505 | $80.69 | $3,510,418 |
| Mar 12, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −65,517 | $81.74 | $5,355,360 |
| Mar 12, 2026 | Dianthus Therapeutics Inc. | Open-market sale | −12,796 | $82.60 | $1,056,950 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.